The FDA assessed the safety and effectiveness of atidarsagene autotemcel determined by facts from 37 children who received atidarsagene autotemcel in two solitary-arm, open-label scientific trials As well as in an expanded accessibility application.[7] Kids who obtained treatment with atidarsagene autotemcel were being when compared with untreated